News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jan 27, 2023 StatementCOVID-19 Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting Download Jan 18, 2023 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster Download Dec 30, 2022 COVID-19Seasonal influenza Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Download Dec 16, 2022 StatementGlobal healthCOVID-19 German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster Download Dec 7, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents Download Nov 29, 2022 COVID-19 World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults Download Nov 23, 2022 StatementCOVID-19 Termination of COVID-19 Vaccine Purchase Agreement with Gavi Download Nov 18, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults Download Nov 9, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults Download Nov 8, 2022 COVID-19 Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster Download Oct 20, 2022 COVID-19Seasonal influenza Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022 Download Oct 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Download Oct 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults Download Oct 13, 2022 COVID-19Seasonal influenza Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains Download Oct 12, 2022 COVID-19 Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants Download Oct 10, 2022 COVID-19Seasonal influenza Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022 Download Sep 27, 2022 COVID-19 Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom Download Sep 16, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17 Download Sep 16, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older Download Sep 13, 2022 COVID-19 Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older Download Sep 12, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older Download Sep 2, 2022 COVID-19 Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older Download Sep 2, 2022 StatementCOVID-19 World Health Organization Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine Download Sep 1, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older Download Aug 26, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17 Download Show 5102550100 per page«12345678»